---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-027383"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:29:00.989725+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals CEO Stephen Willard recommends new CEO with commercial pharma experience; search initiated

## Summary
- Stephen Willard, CEO of NRx Pharmaceuticals, recommended that the company's shareholders would be best served by a CEO with commercial pharmaceutical experience, particularly drug launch experience.
- The company has initiated a search for a new CEO possessing the desired qualifications; Mr. Willard will continue as CEO during the search.
- Mr. Willard stated his recommendation is not the result of any disagreement regarding the company's operations, policies, or practices.

## SEC filing metadata
- accession: 0001437749-24-027383
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774924027383/0001437749-24-027383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774924027383/nrxp20240820_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-027383
- JSON: https://secwatch.observer/filing/0001437749-24-027383.json
- Plain text: https://secwatch.observer/filing/0001437749-24-027383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.